001     137778
005     20240321220320.0
024 7 _ |a 10.3233/JAD-142094
|2 doi
024 7 _ |a pmid:25374103
|2 pmid
024 7 _ |a 1387-2877
|2 ISSN
024 7 _ |a 1875-8908
|2 ISSN
037 _ _ |a DZNE-2020-04100
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Saidi, Laiq-Jan
|0 P:(DE-2719)2810958
|b 0
|e First author
245 _ _ |a Carboxy terminus heat shock protein 70 interacting protein reduces tau-associated degenerative changes.
260 _ _ |a Amsterdam
|c 2015
|b IOS Press
264 _ 1 |3 print
|2 Crossref
|b IOS Press
|c 2015-02-06
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1710943547_2063
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a One of the hallmarks of Alzheimer's disease is the formation of neurofibrillary tangles, intracellular aggregates of hyperphosphorylated, mislocalized tau protein, which are associated with neuronal loss. Changes in tau are known to impair cellular transport (including that of mitochondria) and are associated with cell death in cell culture and mouse models of tauopathy. Thus clearing pathological forms of tau from cells is a key therapeutic strategy. One critical modulator in the degradation and clearance of misfolded proteins is the co-chaperone CHIP (Carboxy terminus Hsp70 interacting Protein), which is known to play a role in refolding and clearance of hyperphosphorylated tau. Here, we tested the hypothesis that CHIP could ameliorate pathological changes associated with tau. We find that co-expressing CHIP with full-length tau, tau truncated at D421 mimicking caspase cleavage, or the short tauRDΔK280 tau construct containing only the tau repeat domain with a tauopathy mutation, decreases tau protein levels in human H4 neuroglioma cells in a manner dependent on the Hsp70-binding TPR domain of CHIP. The observed reduction in tau levels by CHIP is associated with a decrease of tau phosphorylation and reduced levels of cleaved Caspase 3 indicating that CHIP plays an important role in preventing tau-induced pathological changes. Furthermore, tau-associated mitochondrial transport deficits are rescued by CHIP co-expression in H4 cells. Together, these data suggest that the co-chaperone CHIP can rescue the pathological effects of tau, and indicate that other diseases of protein misfolding and accumulation may also benefit from CHIP upregulation.
536 _ _ |a 342 - Disease Mechanisms and Model Systems (POF3-342)
|0 G:(DE-HGF)POF3-342
|c POF3-342
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a HSP70 Heat-Shock Proteins
|2 NLM Chemicals
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 7 |a Green Fluorescent Proteins
|0 147336-22-9
|2 NLM Chemicals
650 _ 7 |a STUB1 protein, human
|0 EC 2.3.2.27
|2 NLM Chemicals
650 _ 7 |a Ubiquitin-Protein Ligases
|0 EC 2.3.2.27
|2 NLM Chemicals
650 _ 7 |a Caspase 3
|0 EC 3.4.22.-
|2 NLM Chemicals
650 _ 2 |a Caspase 3: pharmacology
|2 MeSH
650 _ 2 |a Cell Line, Tumor
|2 MeSH
650 _ 2 |a Cell Proliferation: genetics
|2 MeSH
650 _ 2 |a Gene Expression Regulation: drug effects
|2 MeSH
650 _ 2 |a Gene Expression Regulation: genetics
|2 MeSH
650 _ 2 |a Green Fluorescent Proteins: genetics
|2 MeSH
650 _ 2 |a Green Fluorescent Proteins: metabolism
|2 MeSH
650 _ 2 |a HSP70 Heat-Shock Proteins: genetics
|2 MeSH
650 _ 2 |a HSP70 Heat-Shock Proteins: metabolism
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Mitochondria: metabolism
|2 MeSH
650 _ 2 |a Mutation: genetics
|2 MeSH
650 _ 2 |a Neuroblastoma: pathology
|2 MeSH
650 _ 2 |a Protein Binding: drug effects
|2 MeSH
650 _ 2 |a Transfection
|2 MeSH
650 _ 2 |a Ubiquitin-Protein Ligases: genetics
|2 MeSH
650 _ 2 |a Ubiquitin-Protein Ligases: metabolism
|2 MeSH
650 _ 2 |a tau Proteins: genetics
|2 MeSH
650 _ 2 |a tau Proteins: metabolism
|2 MeSH
700 1 _ |a Polydoro, Manuela
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Kay, Kevin R
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Sanchez, Laura
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Mandelkow, Eva-Maria
|0 P:(DE-2719)2541658
|b 4
700 1 _ |a Hyman, Bradley T
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Spires-Jones, Tara L
|0 P:(DE-HGF)0
|b 6
|e Corresponding author
773 1 8 |a 10.3233/jad-142094
|b : IOS Press, 2015-02-06
|n 3
|p 937-947
|3 journal-article
|2 Crossref
|t Journal of Alzheimer's Disease
|v 44
|y 2015
|x 1875-8908
773 _ _ |a 10.3233/JAD-142094
|g Vol. 44, no. 3, p. 937 - 947
|0 PERI:(DE-600)2070772-1
|n 3
|q 44:3<937 - 947
|p 937-947
|t Journal of Alzheimer's disease
|v 44
|y 2015
|x 1875-8908
856 4 _ |u https://pub.dzne.de/record/137778/files/DZNE-2020-04100_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/137778/files/DZNE-2020-04100_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:137778
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2810958
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2541658
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-342
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms and Model Systems
|x 0
914 1 _ |y 2015
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J ALZHEIMERS DIS : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-2719)1013015
|k AG Mandelkow 2
|l Cell and Animal Models of Neurodegeneration
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1013015
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21